DPYD genotype-guided fluoropyrimidines dose: is it ready for prime time?

Ann Oncol. 2017 Dec 1;28(12):2913-2914. doi: 10.1093/annonc/mdx632.

Authors

D Páez¹, R Salazar², J Tabernero³

Affiliations

¹ Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.
² Medical Oncology Department, Catalan Institute of Oncology (ICO), CIBERONC, L'Hospitalet de Llobregat, Barcelona.
³ Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), CIBERONC, Universitat Autònoma de Barcelona, Barcelona, Spain.

PMID: 29045550
DOI: 10.1093/annonc/mdx632

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antimetabolites, Antineoplastic
Dihydrouracil Dehydrogenase (NADP) / genetics*
Fluorouracil
Genotype*
Humans

Substances

Antimetabolites, Antineoplastic
Dihydrouracil Dehydrogenase (NADP)
Fluorouracil